Company data
Summit Therapeutics Inc. employees and revenue per employee
SMMT · Biotechnology · $7.96B market cap
Summit Therapeutics Inc. had 76 employees at the end of fiscal Dec 2022, down 27.6% from a year earlier. Revenue for the year was $583,190, down 56.4% from a year earlier, or $8K per employee. Revenue fell, and headcount fell or held flat with it.
The latest annual report we hold is more than two years old, so these numbers may be out of date.
Employees
76
-27.6% YoY
Revenue
$583,190
-56.4% YoY
Revenue / employee
$8K
Peer median $455K
Rank in industry
106 of 111
Biotechnology
Open roles
54
711 per 1,000 staff
Headcount against revenue
Both lines start at 100 in the first year we hold, so you can see which one grew faster.
Hover a year for the numbers.
| Year ending | Employees | Revenue | Per employee | Staff YoY | Revenue YoY |
|---|---|---|---|---|---|
| Dec 2022 | 76 | $583,190 | $8K | -27.6% | -56.4% |
| Dec 2021 | 105 | $1.3M | $13K | +32.9% | +112.7% |
| Dec 2020 | 79 | $628,875 | $8K | — | — |
Open roles on its job board: 54 (711 per 1,000 staff, against its latest annual headcount), as of 2026-11-20. Tracked since 2026-10-03. No 90 day change yet.
Summit Therapeutics Inc. against similar companies
The closest industry peers by revenue, from Biotechnology.
| Company | Employees | Revenue | Revenue / employee | Shape |
|---|---|---|---|---|
| CGON CG Oncology Inc. | 142 | $4.0M | $28K | Efficient growth |
| STTK Shattuck Labs, Inc. | 40 | $1.0M | $25K | Contracting |
| DNTH Dianthus Therapeutics, Inc. | 92 | $2.0M | $22K | Hiring into decline |
| ABSI Absci Corporation | 140 | $2.8M | $20K | Contracting |
| INBX Inhibrx Biosciences Inc. | 109 | $1.3M | $12K | Leaner |
| NGNE Neurogene Inc. | 107 | $925,000 | $9K | — |
| SMMT Summit Therapeutics Inc. | 76 | $583,190 | $8K | Contracting |
| CLDX Celldex Therapeutics, Inc. | 198 | $1.5M | $8K | Hiring into decline |
| ARTV Artiva Biotherapeutics, Inc. | 89 | $251,000 | $3K | — |
Questions about Summit Therapeutics Inc.
- How many employees does Summit Therapeutics Inc. have?
- Summit Therapeutics Inc. reported 76 employees for the fiscal year ending Dec 2022, in the annual report it filed on March 9, 2023. That is down 27.6% from a year earlier.
- What is Summit Therapeutics Inc.'s revenue per employee?
- Summit Therapeutics Inc. brought in $583,190 of revenue in fiscal Dec 2022, which is $8K per employee. That ranks 106 of 111 companies we track in Biotechnology, where the median is $455K.
- Is Summit Therapeutics Inc. hiring?
- Summit Therapeutics Inc.'s public job board listed 54 open roles on November 20, 2026, about 711 per 1,000 staff.
- Where do these numbers come from?
- Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.
Outpick research
This page is the filings. The research is a membership.
On the first and third Friday of each month Outpick publishes one stock pick with the full case for owning it, adds it to a live portfolio you can audit, and writes a note when a position closes. A new account gets 21 days of the whole membership with no card, and nothing is charged when it ends.
Free game
Think you can pick better than the S&P 500?
Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.
Enter the challengeMore data
Compare SMMT with the rest of the market
See who earns the most per employee, who is hiring, and who is cutting, across every company we track.
Source: employee counts and revenue as stated in Summit Therapeutics Inc.'s annual reports (Form 10-K), latest filed March 9, 2023. This is data, not a recommendation to buy or sell SMMT.